Study to Determine the Pharmacokinetics and Pharmacodynamic Effects of Phenylephrine on BP Via IV

  • End date
    Jun 25, 2022
  • participants needed
  • sponsor
    West-Ward Pharmaceutical
Updated on 25 January 2021


The primary objective of this study is to evaluate the dose effect of Phenylephrine Hydrochloride Injection on the treatment of clinically relevant decreased blood pressure in the pediatric population, 12 to 16 year old patients undergoing general and neuraxial anesthesia.

The secondary objectives are to describe changes in blood pressure and heart rate, time to onset and to maximal response, and the duration of response; to assess the safety of the product in this population; and to characterize the pharmacokinetics of phenylephrine hydrochloride.


This is a Phase 4 multi-center, randomized open-label study in 100 subjects aged 12 to 16 years who experience a decrease in blood pressure during a procedure requiring general or neuraxial anesthesia. At least 300 subjects will be enrolled in this study. It is anticipated that up to 33% of enrolled subjects will actually experience a decrease in blood pressure that requires treatment and so will receive Phenylephrine Hydrochloride Injection (PHI). There are 12 possible randomization assignments: one of six initial treatments PHI will be initially administered to approximately 50 subjects as an intravenous bolus (IV-B) at Low (1 g/kg), Med (3 g/kg), or High (5 g/kg) level; PHI will be initially administered to approximately 50 subjects as a continuous intravenous infusion (IV-I) at Low (0.25 g/kg/min), Med (0.75 g/kg/min), or High (1.25 g/kg/min) level]; each initial treatment group will have two pharmacokinetics (PK) sampling schedules.

Condition Hypotension, Vascular Diseases, Low Blood Pressure (Hypotension)
Treatment Phenylephrine
Clinical Study IdentifierNCT02323399
SponsorWest-Ward Pharmaceutical
Last Modified on25 January 2021


Yes No Not Sure

Inclusion Criteria

Is your age between 12 yrs and 16 yrs?
Gender: Male or Female
Do you have any of these conditions: Hypotension or Low Blood Pressure (Hypotension) or Vascular Diseases?
Do you have any of these conditions: Vascular Diseases or Hypotension or Low Blood Pressure (Hypotension)?
Subject's age is between 12 and 16 years, inclusive
Subject is scheduled for a procedure that requires general or neuraxial anesthesia
Subjects must have normal or clinically acceptable physical exam
Subjects with controlled diabetes prior to entry must have a mean systolic/diastolic office blood pressure 128/78 mmHg (sitting, after 5 minutes of rest)
Females must have a urine or serum pregnancy test (Human Chorionic Gonadotropin) that is negative at Screening and Day 1
Subject's parent or legal guardian gives informed consent and subject gives assent

Exclusion Criteria

Subject has a contraindication to vasoconstrictor therapy for control of blood pressure
Subject has participated in other clinical trials for investigational drugs and/or devices within 30 days prior to enrollment
Subject has any serious medical condition which, in the opinion of the investigator, is likely to interfere with study procedures
Subjects who have a history of any clinically significant local or systemic infectious disease within four weeks prior to initial treatment administration
Subjects who are positive for hepatitis B surface antigen or hepatitis C antibody
Subjects taking antihypertensive medication
Subject is moribund (death is likely to occur in less than 48 hours)
Females who are pregnant, nursing or unwilling to use/practice adequate contraception
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note